REFERENCES
1. Stark BA, Decleene NK, Desai EC, et al. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. JACC. 2025;86:2167-243.
2. Jung M, Schmidt A, Sansonetti M, et al. Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction. Eur Heart J. 2026;47:2831-47.
3. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255-65.
4. Wang J, Gan Y, Cao J, Dong X, Ouyang W. Pathophysiology of stress granules: an emerging link to diseases (Review). Int J Mol Med. 2022;49:44.
5. Huang R, Cai L, Ma X, Shen K. Autophagy-mediated circHIPK2 promotes lipopolysaccharide-induced astrocytic inflammation via SIGMAR1. Int Immunopharmacol. 2023;117:109907.
6. Halabi N, Thomas B, Chidiac O, et al. Dysregulation of long non-coding RNA gene expression pathways in monocytes of type 2 diabetes patients with cardiovascular disease. Cardiovasc Diabetol. 2024;23:196.
7. Makkar SK. Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives. Front Genet. 2025;16:1675209.
8. Zhang X, Qiu L, Sultan DH, et al. Development of a CCR2 targeted 18F-labeled radiotracer for atherosclerosis imaging with PET. Nucl Med Biol. 2024;130-1:108893.
9. Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation, aging, and cardiovascular disease. J Am Coll Cardiol. 2022;79:837-47.
10. Caudal A, Snyder MP, Wu JC. Harnessing human genetics and stem cells for precision cardiovascular medicine. Cell Genom. 2024;4:100445.
11. Loan Young T, Chang Wang K, James Varley A, Li B. Clinical delivery of circular RNA: lessons learned from RNA drug development. Adv Drug Deliv Rev. 2023;197:114826.
12. Wang X, Chen L, Wei J, et al. The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications. Sig Transduct Target Ther. 2025;10:166.
